Human CCR8 Protein (VLP)

AIDD‑Ready
Related Products: Cell line CHEK-ATP140
Cat. No. / Size
Price
Availability
Qty
CC8-H52P5-20ug
$620.00
In Stock - Delivery in 1-2 business days
CC8-H52P5-100ug
$1,235.00
In Stock - Delivery in 1-2 business days
CC8-H52P5-500ug (250ug X 2)
$4,305.00
In Stock - Delivery in 1-2 business days
CC8-H52P5
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Application
  • Immunization
  • Cell based assay (FACS or functional assay)
  • Screening (ELISA)
Synonyms

CC chemokine receptor 8, CDw198, ChemR1, CKRL1, CKR-L1, CKRL1, CY6, GPRCL1, GPRCY6, GPR-CY6, TER-1

Source

Human CCR8 Protein (VLP) (CC8-H52P5) is expressed from human 293 cells (HEK293). It contains AA Asp 2 - Ser 318 (Accession # P51685-1).

Predicted N-terminus: Asp

Molecular Characterization

Within the expressed region, several mutations were introduced to optimize the protein expression and stability.

*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

Structure

Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

Synthesis Process

Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SEC-HPLC.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.

Background

A chemokine receptor predominantly marking tumor-infiltrating regulatory T cells (Tregs) rather than peripheral Tregs. Targeting CCR8 enables selective depletion of immunosuppressive cells within the tumor microenvironment, thereby reinvigorating anti-tumor immunity without triggering systemic autoimmunity.